Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
Going Beyond the Blood-Brain Barrier: Delivery of Diverse Cargo to Targeted Cells Within the Central Nervous System, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about going beyond the blood-brain barrier through the delivery of diverse cargo within the central nervous system (CNS).
-
Scientists at SRI International have developed a peptide that targets lung tumors and delivers therapeutics inside the cells
The newly optimized molecular vehicle provides effective, targeted delivery of anticancer agents to lung tumors.
-
Women participants needed for NIH funded research study on memory and sleep
We are looking for healthy women to participate in an NIH funded research study exploring the impact of sex hormones on memory and sleep.
-
SRI International celebrates global recognition of Bioinformatics Research Group and its BioCyc and Pathway Tools collection
SRI’s BioCyc and Pathway Tools publication contributors named to 2022 Highly Cited Researchers List; EcoCyc selected as Global Core Biodata Resource.
-
Menopause goes high tech: Understanding your menopause journey by leveraging AI and wearable sensing technology
SRI spinout Lisa Health tackles the menopause gap with AI, digital therapeutics and a new app.
-
SRI International expanding BioCyc database collection for genomic researchers
BioCyc database reaches 20,000 genomes ahead of collaboration with Wolters Kluwer.
-
Scrutinizing a new sleep technology frontier
SRI’s Human Sleep Lab puts consumer wearables to the test.
-
How the COVID-19 pandemic and machine learning delivered insights into adolescent mental health
An ABCD Study® paper delivers insights into the pandemic’s impact on adolescents.
-
SRI International announces collaboration agreement with Janssen
Collaboration focuses on SRI’s Synfini artificial intelligence and automation platform to accelerate small-molecule drug discovery.
-
SRI Bioscience awarded $14.7 million contract to continue development of high-concentration Naloxone formulation
SRI Biosciences has been awarded a contract sponsored by the Defense Threat Reduction Agency (DTRA) to continue development of a high-concentration naloxone product.
-
Automating chemical drug discovery and synthesis
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
-
Intracellular delivery—now a reality for many types of therapeutics
Unlocking the therapeutic potential of antisense oglionucleotides and other biologics.